AffiliationGenetics Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02115, USA.
MetadataShow full item record
AbstractBRAF mutations play a well-established role in melanomagenesis; however, without additional genetic alterations, tumor development is restricted by oncogene-induced senescence (OIS). Here, we show that mutations in the NF1 tumor suppressor gene cooperate with BRAF mutations in melanomagenesis by preventing OIS. In a genetically engineered mouse model, Nf1 mutations suppress Braf-induced senescence, promote melanocyte hyperproliferation, and enhance melanoma development. Nf1 mutations function by deregulating both phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways. As such, Nf1/Braf-mutant tumors are resistant to BRAF inhibitors but are sensitive to combined inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase and mTOR. Importantly, NF1 is mutated or suppressed in human melanomas that harbor concurrent BRAF mutations, NF1 ablation decreases the sensitivity of melanoma cell lines to BRAF inhibitors, and NF1 is lost in tumors from patients following treatment with these agents. Collectively, these studies provide mechanistic insight into how NF1 cooperates with BRAF mutations in melanoma and show that NF1/neurofibromin inactivation may have an impact on responses to targeted therapies.
CitationElucidating distinct roles for NF1 in melanomagenesis. 2013, 3 (3):338-49 Cancer Discov
- An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.
- Authors: Gibney GT, Smalley KS
- Issue date: 2013 Mar
- A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
- Authors: Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA
- Issue date: 2013 Mar
- Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
- Authors: Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB
- Issue date: 2014 Apr 15
- RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
- Authors: Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F
- Issue date: 2010 Jul 1
- Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
- Authors: Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ
- Issue date: 2016 Dec 13